Scancell Share Discussion Threads

[plasybryn] 05/9/2023 21:16

https://www.trinitydelta.org/wp-content/uploads/2023/09/SCLP-Update-230905.pdf

[the real lozan] 05/9/2023 20:09

Why I left England 20 odd YEARS ago -

For landan,,, substitute England
It was BAD enough living in a downward spiraling England pre 20 odd YEARS ago
We saw what was coming,but,I must admit, I didn't realise 'just how bad it would become'
Then
This is EXACTLY what these SCLP forums have become
Only, the SCLandanerP people don't recognise themselves as the people described in

[inanaco] 05/9/2023 17:24

keeping it simple ..........

Multiple catalysts could drive significant upside Catalysts include: (1) Stage one SCIB1 doublet combination data in Q423 (9 responses from up to n=15) with stage two data (28 responses from up to n=43) expected in H124; (2) iSCIB1+ doublet combination top-line data in H124; (3) Modi-1 CPI combination data in 2024 from various cohorts; (4) partnering optionality with the GlyMab antibody platform.


get 9 from 15 and we are on target


with the balance of patients treated with Iscib1

if that proves itself at phase 1


we have a phase 2/3 registrational trial with a patent till 2037

that is the real world of no risk ...

did scib1 in the earlier trials fail ........ NO it was better than expected ... and iscib's are more potent

ATB

[ivyspivey] 05/9/2023 14:56

P7,
Your use of correlation and statistics is reminiscent of the old linkage between rum consumption and number of Methodist ministers in the West Indies so not always closely correlated lol.
There are many causal links between rise of autism and other factors not related to any vaccine.
However I do remember the Andrew Wakefield intervention suggesting along similar lines to yourself about use of MMR which affected the uptake.
The direct consequence of that intervention was the death and severe implications for many unprotected children so that was as a direct result of anti Vax sentiment.
That is why I am a great believer in the power of Vaccination?
Others disagree which is their prerogative and we all have individual choice so I have made mine to get fully Vaccinated whereas you have taken a different view.
No worries either way

[rogerbridge] 05/9/2023 14:28

Added today.

[marcusl2] 05/9/2023 14:18

Initial SCIB1 combo data could provide first important insights Initial data from the first stage (Cohort 1 in up to 15 patients) of the Phase II SCOPE trial of SCIB1 in combination with checkpoint inhibitors (CPIs) in advanced melanoma are expected during Q423. To validate the hypothesis that SCIB1 could have synergistic effects with doublet therapy (nivolumab + ipilimumab) nine responses are required (>55% response rate). If nine responses are achieved in fewer than 15 patients, for a higher response rate, this would suggest that SCIB1 + doublet therapy could meaningfully improve current outcomes, which would be a significant achievement, in our view.

Second-generation iSCIB1+ could broaden the addressable market Scancell’s AvidiMab platform has been used to enhance SCIB1, with SCIB1 limited to the c 30-40% of patients that have the appropriate human leukocyte antigen type. The enhanced second-generation programme, iSCIB1+, can address 100% of melanoma patients, broadening the target market, and is also more potent. Scancell intends to transition the SCOPE study to iSCIB1+ in combination with doublet therapy in Q423 for initial data H124. Preclinical data suggest the benefits of iSCIB1+ (performance, efficacy, and ease of admin) are a significant advance over SCIB1.

Data for lead Moditope vaccine, Modi-1, are expected 2024 The Phase I/II ModiFY trial of Modi-1 as monotherapy and in combination with CPIs in various challenging solid tumours is ongoing. Initial early signals of efficacy have already been observed in various monotherapy cohorts and further data are expected in 2024. The CPI combination data will be particularly important for understanding Modi-1’s positioning and potential, and will be a key de-risking event.

Multiple catalysts could drive significant upside Catalysts include: (1) Stage one SCIB1 doublet combination data in Q423 (9 responses from up to n=15) with stage two data (28 responses from up to n=43) expected in H124; (2) iSCIB1+ doublet combination top-line data in H124; (3) Modi-1 CPI combination data in 2024 from various cohorts; (4) partnering optionality with the GlyMab antibody platform.

[marcusl2] 05/9/2023 14:18

Let the doubters enjoy their day.

The Trinity report is good enough for me. Roll on further data for Moditope, Scib, Avidimab and further deals for the Glymabs.


I think those buying at these levels will be the people laughing next year.

[marcusl2] 05/9/2023 13:56

Scancell has several key clinical data points due through to end-2024. First data will be from the Phase II trial of SCIB1 in combination with checkpoint inhibitors (CPIs) in advanced skin cancer. If successful the study will transition to the enhanced iSCIB1+ formulation that offers greater potency and broader applicability. If SCIB1 promising early data mature as hoped, then this programme could improve current outcomes. Top-line Modi-1 CPI combination data in multiple tumours are expected in 2024. The antibody platforms, GlyMab and AvidiMab, provide attractive out-licensing opportunities. Our Scancell rNPV valuation remains £300.1m, or 36.7p/share.

[the real lozan] 05/9/2023 13:55

5612 -
"I know this is finger in the air stuff but....."
Blah blah blah
Indeed this sales patter SOUNDS good doesn't it
What could possibly go wrong ???

[marcusl2] 05/9/2023 13:44

I know this is finger in the air stuff but.....

Hidden value

Trinity April 2022

Moditope Platform £3,500m peak sales

Immunobody platform £2,500m " "

Glymabs £5,000m " "

Avidimab £8,500m "


Since then we have proof that Avidimab works, first deal for a Glymab and Modi & Scib updates are coming in Sept and OCT.




Scancell mkt cap $80m

[the real lozan] 05/9/2023 13:29

Breaking news -
Following remarkable results of trials, carried out in Innanacombe Devon ... Landan is to adopt and enforce 'ULIQZ's .

[panama7] 05/9/2023 12:52

Ivy, as someone who was at Merck when they produced the MMR vaccine would you like to comment on the recent Federal Judge Ruling. The CDC must remove from their website " The MMR vaccine does not cause Autism." Perhaps you would like to research the rise in Autism coinciding with the number of vaccines kids now need to take.

[inanaco] 05/9/2023 10:40

in simplest form

most vaccines have to be taken up by the dendritic cells

scancell targets the dendritic cells .......

a huge difference because we target a very specific dendritic cell that carries the CD64 receptor

these are double activated by the vaccine ......... from two sources direct and indirect

[inanaco] 05/9/2023 10:33

you need to look at how immunobody works .. completely different way to most other vaccines

[inanaco] 05/9/2023 10:25

Or you don't become ill at all ......... the vaccine has done its job ... the virus never gets a foot hold .... example

Polio

small pox

.................

jackdaw99

Posts: 1,219

Price: 8.75

No Opinion

RE: Level 2Today 10:11
Disingenuous. Can you name a vaccine that does either or both? What vaccines do is sensitise your immune system against a 'real' infection that you have not yet met, in effect simulating a natural disease with a less-dangerous 'artificial' version. This means that, when you meet the 'real' thing you will mount not a primary (=slow) immune response but a much faster and stronger (=secondary) immune response. So you become less ill. A vaccine does not prevent you being infected with the real disease, nor does it prevent you either infecting nor becoming infected by others. So, while it is true that no vaccine 'stops' spread or infection by its primary effect, they reduce the effects of an infection and, by doing so, may have consequences upon both (eg by getting on top of an infection rapidly, because of strong secondary response, there may be fewer transmissible virus/bacterium particles to infect others). Hope that helps.

[the real lozan] 05/9/2023 10:15

This is sooo easy -
To take from the 'sheep' who THINK they know what they are doing....they DON'T
Create/allow a GREED situation where the unwary 'flock in' thinking they know better, then repeatedly 'pick their pockets'.
trHYPE *experts* assist the exploitation
The sheep do not realise who is actually in CONtrol of S P, the sheep THINK they are.
.
SPIKES = Push up the S P, DROP the S P - the sheepand their money are trapped-in
= LOSSES
PANIC = Deflate the S P, the sheep panic sell = LOSSES
.
Wash,rinse and repeat
And STILL the sheep who THINK/believe (assisted in part by the trHYPE) that ONLY they know what they are doing- turn-up for more.
.
For REAL market players / REAL S P CONtrolers - this is a gift that keeps giving

[inanaco] 05/9/2023 10:08

exactly its cheap .......... and for some unknown reason you think i have missed that

ATB

[ivyspivey] 05/9/2023 10:02

Morning Tosh don’t be too hard on him as he had an expensive haircut yesterday and cost him at last £10k plus his car park so he may well have been selling at 8p as a distressed seller unless he has put the field on the market.
Surely he must have learned his lesson from yesterday that potentially losing £50k on the basis of one comment on another forum that he has absolutely no control over does not register on his radar.
As AB said on LSE if you had had limited exposure you can take advantage of the situation like some of us did this morning.

[marcusl2] 05/9/2023 09:18

Market cap was £71m this morning.

Modi-1 could be very valuable if more Cohort 4 patients show regression. Remember theese are end stage and very ill patients. Moditope may get approved for earlier stage patients and be even more effective.


Immunobody Scib-1 plus doublet looking good, iScib soon hopefully.

Avidimab

Glymabs (one deal already)


Scancell can earn up to a maximum US$624mln if Genmab develops and commercialises all modalities plus royalties on net sales.

[inanaco] 05/9/2023 09:13

you will be better informed to make that statement by Dec/jan .... Tosh

No risk applies to SCIB1 ... read the posts its our fall back asset

ATB